Insider Selling: United Therapeutics (NASDAQ:UTHR) Director Sells 2,910 Shares of Stock

Key Points

• Director Christopher Patusky sold 2,910 shares of United Therapeutics on April 24 at an average price of $569, totaling $1,655,790 and reducing his holding by 66.14% to 1,490 shares.
• United Therapeutics beat quarterly EPS expectations with $7.70 EPS (vs. $6.78 est.) while reporting $790.2M revenue (below the $814.8M estimate) and a net margin of 41.94%.
• Analyst sentiment is largely positive with a consensus rating of “Moderate Buy” and a consensus target price of $601.50; the stock trades near $567 with a market cap of about $24.86 billion and a 52‑week range of $272.12–$607.89.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) Director Christopher Patusky sold 2,910 shares of United Therapeutics stock in a transaction on Friday, April 24th. The stock was sold at an average price of $569.00, for a total transaction of $1,655,790.00. Following the sale, the director directly owned 1,490 shares of the company's stock, valued at $847,810. This represents a 66.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Christopher Patusky also recently made the following trade(s):

• On Friday, April 17th, Christopher Patusky sold 1,000 shares of United Therapeutics stock. The stock was sold at an average price of $578.88, for a total transaction of $578,880.00.

United Therapeutics Stock Performance

UTHR traded down $5.69 during trading on Friday, reaching $567.16. 264,756 shares of the company's stock were exchanged, compared to its average volume of 491,071. The company's fifty day moving average price is $534.64 and its 200-day moving average price is $493.24. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $607.89. The firm has a market capitalization of $24.86 billion, a PE ratio of 20.33, a P/E/G ratio of 1.63 and a beta of 0.75.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping analysts' consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The firm had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. During the same quarter in the previous year, the business earned $6.19 EPS. The business's quarterly revenue was up 7.4% compared to the same quarter last year. Research analysts forecast that United Therapeutics Corporation will post 27.97 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

UTHR has been the topic of a number of recent analyst reports. Wells Fargo & Company lifted their price target on shares of United Therapeutics from $486.00 to $575.00 and gave the stock an "equal weight" rating in a research report on Tuesday, March 31st. UBS Group lifted their price target on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a "buy" rating in a research report on Thursday, March 5th. Jefferies Financial Group reissued a "buy" rating on shares of United Therapeutics in a research report on Monday, March 2nd. Royal Bank Of Canada lifted their price target on shares of United Therapeutics from $587.00 to $643.00 and gave the stock an "outperform" rating in a research report on Thursday, February 26th. Finally, Weiss Ratings reissued a "buy (b)" rating on shares of United Therapeutics in a research report on Monday, December 29th. Ten investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, United Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $601.50.

Institutional Investors Weigh In On United Therapeutics

Several institutional investors have recently added to or reduced their stakes in UTHR. Torren Management LLC bought a new stake in United Therapeutics in the 4th quarter valued at $26,000. Activest Wealth Management lifted its position in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 56 shares in the last quarter. WealthCollab LLC lifted its position in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. lifted its position in United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 46 shares in the last quarter. Finally, Entrust Financial LLC bought a new stake in United Therapeutics in the 4th quarter valued at $31,000. 94.08% of the stock is owned by institutional investors.

About United Therapeutics

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.